Against its peers

Eli Lilly (filled) against the other 23 health care companies among the 200 largest in the S&P 500. Tap or hover a dot to read it.

Yahoo Finance, 30 Oct 2026. P/E on the last four quarters' diluted EPS; revenue growth and operating margin for each company's last fiscal year; debt to equity at the last balance sheet; dividend yield on the last 12 months' dividends.

Valuation

A ten-year discounted cash flow model on the last reported free cash flow. Every assumption is on the page: move it and the value follows.

Value per share on these assumptions
Growth the price implies

Base: free cash flow of $6.0bn in the year to Dec 2025, net debt of $46.0bn, 0.89bn shares. Growth fades in a straight line from year 6 to year 10. An Andra Markets model, not a recommendation.

Valuation over time

The price to earnings ratio at each month end, on the last fiscal year’s diluted earnings per share known at the time, against its average over the period.

P/EAverage

Month-end closes and annual reports, via Yahoo Finance.

Where revenue goes

Of every $100 of revenue in the year to Dec 2025, Eli Lilly kept $32 as net income.

Annual report for the year to Dec 2025, via Yahoo Finance. Items under 0.5% of revenue are folded into the next line.

Revenue and profit, 4 years

Revenue and net income each fiscal year, in billions of dollars. Tap or hover a year to read it.

RevenueNet income

Annual reports, via Yahoo Finance.

Last 5 quarters

Revenue in billions of dollars and diluted earnings per share, quarter by quarter.

Revenue

Earnings per share

Quarterly reports, via Yahoo Finance. Quarters are named by the month they end.

Cash flow and investment

Cash from operations, what went into capital spending, and the free cash flow left, in billions of dollars.

Cash from operationsCapital spendingFree cash flow

Annual reports, via Yahoo Finance.

Balance sheet

Cash and short-term investments, debt and shareholders’ equity at each fiscal year end, in billions of dollars.

Cash and investmentsDebtEquity

Annual reports, via Yahoo Finance. Debt excludes leases.

Returns to shareholders

Dividends paid and shares bought back each fiscal year, against net income, in billions of dollars.

DividendsBuybacksNet income

Annual reports, via Yahoo Finance.

Share price returns

Price change over each period to the close of 30 Oct 2026, without dividends.

Series1 month3 monthsYear to date1 year
Eli Lilly+23.3%+26.4%+31.9%+64.3%
Health care average (24)+10.9%+24.1%+41.8%+52.7%
S&P 500−1.1%−0.3%+10.7%+10.8%

Yahoo Finance daily closes, in dollars. The sector average is the simple average of its companies among the 200 largest in the S&P 500.

Against the market

Eli Lilly and the S&P 500 over the past year, both rebased to 100, each in its own currency.

Eli LillyS&P 500

Yahoo Finance, daily closes to 30 Oct 2026.

Risk

How much the shares move, and how far they have fallen from their high over the past year.

  • Volatility, 1 year36%Annualised daily moves; the S&P 500 moved 13%
  • Beta to the S&P 5000.241.0 moves with the market
  • Deepest fall, 1 year−23.3%25 Nov 2025 to 29 Apr 2026
  • Below its highAt its highAgainst the year’s highest close

Yahoo Finance daily closes. Beta from daily returns against the S&P 500.

News

The latest headlines on Eli Lilly from the past week. Each opens on its publisher’s site.

    Finnhub company news, refreshed every 15 minutes. Andra Markets does not write or check these headlines.

    What analysts say

    Finnhub recommendation trends, monthly. Not a recommendation from Andra Markets.

    Investment memo

    Coming with the Andra Markets subscription: a full memo on Eli Lilly, written for professionals.

    • The thesis and what would change it
    • Segment by segment, with the model's full workings
    • Three scenarios with their assumptions
    • What to watch at the next results

    Ahead

    No results date in the calendar yet. It appears here once the company or Yahoo Finance posts one.